EATONTOWN, N.J., April 24, 2014 (GLOBE NEWSWIRE) -- American CryoStem Corporation (OTCQB:CRYO), a leading biotechnology developer and licensor of patented adipose tissue-based adult stem cell technologies, today announced that its ACS Laboratory division has completed its quarterly laboratory R&D program ahead of schedule, yielding new intellectual property and positive results for expanding and differentiating adipose-derived stem cells (ADSCs). Breakthroughs in American CryoStem's proprietary cell culture medium (ACSelerateTM) and culturing methodology have enabled the Company to accelerate the robust cellular expansion and rapid differentiation of ADSCs to adipocytes (fat cells), chondrocytes (cartilage-producing cells) and osteocytes (bone-producing cells). Working with its patented media technologies, the Company has been able to accelerate early adipocyte formation to within 24 to 72 hours; to produce chondrocyte filaments contracting into early cartilaginous tissue within 48 to 72 hours; and to form heavily mineralized, trabecular bone tissue within 11 days -- processes that typically require several weeks to complete.
Dr. Michael Moeller, Chief Scientist at American CryoStem, stated, "The development of rapid, efficient and reproducible methods of differentiating distinct mature cells from adipose tissue will prove invaluable to the Regenerative Medicine industry. The ability to quickly grow large numbers of ADSCs from patient samples and to rapidly differentiate them into distinct lineages will open the door to multiple therapeutic and regenerative approaches supported in our ongoing university and corporate collaborations."
"We are pleased with our laboratory's success in developing and improving the Company's products for research and therapeutic applications. This improvement is significant to the industry in that rapid differentiation of harvested adipose derived stem cells can reduce the lead time for proper and complete identification of these cells from weeks to just days," added Anthony Dudzinski, American CryoStem's COO. Continuing, he noted, "Our goal is to improve and accelerate the movement of cellular therapies from the lab to the patient."
About American CryoStem Corporation
A biotechnology pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem operates a state-of-the-art, FDA-registered, clinical laboratory dedicated to processing, bio-banking and development of cellular applications using autologous adipose (fat) tissue and adipose derived stem cells (ADSCs). Through its scientific efforts, the Company has built a strong, strategic portfolio of intellectual property, patent applications, and proprietary operating processes that form its core standardized cellular platform. For more information, please visit www.americancryostem.com and www.acslaboratories.com. You can also find links to blogs, media coverage and press releases on our corporate Facebook, Twitter, and LinkedIn profiles.
Forward Looking Statements
This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.